Dr Reddy’s Laboratories Limited share price is expected to remain in focus after the pharmaceutical company announced the launch of its generic Semaglutide injection in Canada.
The launch follows the receipt of a Notice of Compliance (NOC) from Health Canada on April 28, 2026.
The company stated that Canada has become the first G7 country to grant market authorisation for generic Semaglutide injection, marking a significant milestone for Dr Reddy’s in the GLP-1 therapy segment.
According to the company’s press release, Dr Reddy’s is among the first pharmaceutical companies to introduce a generic Semaglutide injection in the Canadian market.
The treatment is indicated for adults with type 2 diabetes mellitus to improve glycaemic control along with diet and exercise.
The product is being supplied as a sterile solution for subcutaneous injection in a pre-filled pen format and will be available in 2 mg per pen and 4 mg per pen strengths.
The company said the launch demonstrates its readiness to expand access to affordable GLP-1 therapies across global markets.
Erez Israeli, Chief Executive Officer, Dr Reddy’s, said: “We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development.”
GLP-1 therapies have emerged as a major growth segment within the global pharmaceutical industry due to rising demand for diabetes and obesity-related treatments.
The launch is expected to strengthen Dr Reddy’s presence in regulated international markets and expand its diabetes care portfolio.
The company stated that it continues to focus on improving patient access to advanced and affordable therapies while expanding its global footprint across multiple healthcare markets.
Read More: Dr. Reddy’s Share Price in Focus; Revenue Grows 3.2% in FY26 Results!
As of 18 May 2026, at 10:15 AM, Dr Reddy’s share price is trading at ₹1,331.60 per share, reflecting a decline of 0.38% from the previous closing price.
The launch of generic Semaglutide injection in Canada marks a significant regulatory and commercial milestone for Dr Reddy’s as the company expands its presence in the global GLP-1 therapy market.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 18, 2026, 10:18 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
